Université de Paris, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France; Laboratory of Excellence GR-Ex, Paris, France.
College of Medicine, Sultan Qaboos University, Oman.
Int J Infect Dis. 2020 Aug;97:303-305. doi: 10.1016/j.ijid.2020.05.110. Epub 2020 Jun 2.
The coronavirus 2 (SARS-CoV-2) pandemic is viciously spreading through the continents with rapidly increasing mortality rates. Current management of COVID-19 is based on the premise that respiratory failure is the leading cause of mortality. However, mounting evidence links accelerated pathogenesis in gravely ill COVID-19 patients to a hyper-inflammatory state involving a cytokine storm. Several components of the heightened inflammatory state were addressed as therapeutic targets. Another key component of the heightened inflammatory state is hyper-ferritinemia which reportedly identifies patients with increased mortality risk. In spite of its strong association with mortality, it is not yet clear if hyper-ferritinemia in COVID-19 patients is merely a systemic marker of disease progression, or a key modulator in disease pathogenesis. Here we address implications of a possible role for hyper-ferritinemia, and altered iron homeostasis in COVID-19 pathogenesis, and potential therapeutic targets in this regard.
冠状病毒 2(SARS-CoV-2)在各大洲肆虐传播,死亡率迅速上升。目前 COVID-19 的治疗方法基于这样的前提,即呼吸衰竭是导致死亡率的主要原因。然而,越来越多的证据表明,严重 COVID-19 患者的加速发病机制与涉及细胞因子风暴的超炎症状态有关。炎症状态升高的几个组成部分被视为治疗靶点。高度炎症状态的另一个关键组成部分是高铁蛋白血症,据报道它可以识别具有更高死亡风险的患者。尽管它与死亡率密切相关,但目前尚不清楚 COVID-19 患者的高铁蛋白血症是否仅仅是疾病进展的系统标志物,还是疾病发病机制中的关键调节剂。在这里,我们探讨了高铁蛋白血症和 COVID-19 发病机制中铁稳态改变的可能作用,以及这方面的潜在治疗靶点。